/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) declared a special cash dividend of $1.50 per share, payable on July 31, 2026 to shareholders of record on July 23, 2026. The move follows a Strategic Transaction with Apotex Health, through which Cumberland received $100 million in cash and may receive up to $11 million more for inventory and transition services.

The Board also authorized an open-market share repurchase program of up to $5 million and several Board members plan additional share purchases. Cumberland will focus resources on developing ifetroban across multiple Phase 2 programs in rare and progressive diseases. The release also corrects prior references to the record date.

Positive

• $1.50 per share special cash dividend payable July 31, 2026
• Strategic transaction delivered $100 million upfront cash plus up to $11 million additional
• Board authorized open-market share repurchase of up to $5 million
• Board members plan new personal share purchase plans to increase holdings
• Company retains majority stake in Cumberland Emerging Technologies and full ifetroban pipeline
• Ifetroban Phase 2 programs show favorable safety and signals supporting further development

Negative

• None.

News Explained

Cumberland has declared a $1.50-per-share cash dividend, with payment set for July 31, 2026 after the Apotex transaction closed.

The July 13, 2026 corrected release states that Cumberland Pharmaceuticals’ board has authorized and declared a special cash dividend of $1.50 per common share. The dividend is scheduled for July 31, 2026 to holders of record at close on July 23, 2026, so the disclosed state is declared and pending payment. If paid as scheduled, the immediate structural consequence is a cash distribution to eligible existing common holders.

The dividend is described as cash paid per share, while the separately authorized open-market repurchase is capped at $5 million. The repurchase is authorized rather than a committed purchase amount: timing and actual shares depend on stock price, trading volume, market conditions, and other business considerations.

The release says this follows the closed Apotex transaction, which provided $100 million in cash at closing for the FDA-approved product line, with up to $11 million in additional payments expected for inventory and transitional support. The supplied July 1 news record also labels the Apotex transaction closed.

Sources and calculations

• Cumberland Pharmaceuticals corrected special dividend release (2026-07-13)
• Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex (2026-07-01)

News Market Reaction – CPIX

+10.29% 6.7x vol

13 alerts

+10.29% News Effect

+16.0% Peak in 28 hr 9 min

+$10M Valuation Impact

$109.98M Market Cap

6.7x Rel. Volume

On the day this news was published, CPIX gained 10.29%, reflecting a significant positive market reaction. Argus tracked a peak move of +16.0% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $109.98M at that time. Trading volume was exceptionally heavy at 6.7x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

/C O R R E C T I O N – Cumberland Pharmaceuticals Inc./ In the news release, CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE, issued July 13, 2026 by Cumberland Pharmaceuticals Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Record Date is July 23, 2026 & Payment Date is July 31,2026

Corporate and Insider Share Purchase Initiatives to Continue

NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock. The dividend will be payable on July 31, 2026, to the shareholders of record at the close of business on July 23, 2026.

Cumberland previously announced the closing of a Strategic Transaction with Apotex Health, resulting in the integration of the U.S.-branded businesses. Cumberland received $100 million in cash at closing for its line of FDA-approved products. In addition, Cumberland expects to receive up to $11 million in additional payments associated with product inventory and transitional support services.

Following the closing of the transaction with Apotex, an analysis by the company's tax advisors, along with refined financial projections, indicated greater net cash from the transaction than originally projected. Therefore, Cumberland's Board of Directors met to assess the Company's future cash needs and evaluate possible alternatives for the excess capital. 

In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5 million in Cumberland shares over time. The timing and actual number of shares repurchased pursuant the Company's repurchase program will be determined by management depending on a variety of factors, including stock price, trading volume, market conditions, and other general business considerations. Several Board members will also be establishing new share purchase plans to increase their holdings in the Company.

"In keeping with our ongoing commitment to deliver value to our shareholders, we are issuing a special dividend following the strategic transaction, which treats all shareholders equally," said A,J. Kazimi, Cumberland's CEO. "After the payout of $1.50 per share, we believe the Company will still have significant liquidity and financial flexibility to fund our long-term product development efforts, with additional reserves available to address any new opportunities".

Cumberland has retained its robust portfolio of innovative product candidates and its majority ownership position in Cumberland Emerging Technologies Inc. Following the closing, Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases:

• Duchenne Muscular Dystrophy Cardiomyopathy: 
  Cumberland announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with this rare, fatal genetic neuromuscular disease. Interactions with the FDA have been underway regarding study results and requirements for approval. The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations.
  
  
• Systemic Sclerosis: 
  Cumberland has conducted a Phase II clinical study evaluating the safety of ifetroban in patients with this debilitating autoimmune disorder. Evaluation of the study data is underway with top-line results anticipated as the next milestone.
  
  
• Idiopathic Pulmonary Fibrosis: 
  A Phase II study evaluating ifetroban in patients with the most common form of progressive fibrosing interstitial lung disease is actively enrolling at medical centers across the U.S. Favorable interim safety findings have been announced, and the next milestone is the announcement of the efficacy results.
  
  
• Cancer Metastasis: 
  Cumberland, in collaboration with Vanderbilt Health, recently announced the results of a Pilot Study of ifetroban in patients with high-risk solid tumors. The findings suggest the potential to block cancer metastasis, as a favorable trend was identified with fewer deaths due to metastatic disease in those receiving ifetroban rather than a placebo. The Phase 2 clinical trial also found ifetroban to be safe and well tolerated in the oncology patients, supporting further development of the drug to prevent cancer metastasis. 

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.

Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.

For more information, please visit www.cumberlandpharma.com.

Correction: The current version of the release has "July 10" in the sub-headline and first paragraph updated to "July 23", updated verbiage in the beginning and end of the third paragraph, and a sentence added after the first sentence of the fourth paragraph.

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-special-dividend-of-1-50-per-share-302823903.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

What is Cumberland Pharmaceuticals (CPIX) special dividend amount and key dates in July 2026?

Cumberland Pharmaceuticals declared a special cash dividend of $1.50 per share, payable on July 31, 2026 to shareholders of record on July 23, 2026. According to Cumberland Pharmaceuticals, the dividend follows its recent strategic transaction with Apotex Health.

Why is Cumberland Pharmaceuticals (CPIX) paying a $1.50 special dividend after the Apotex transaction?

Cumberland is paying the $1.50 per share special dividend because tax analysis and updated projections showed greater net cash from its Apotex transaction than expected. According to Cumberland Pharmaceuticals, the Board evaluated future cash needs and chose to return excess capital while maintaining liquidity for development.

How much cash did Cumberland Pharmaceuticals (CPIX) receive from the Apotex Health strategic transaction?

Cumberland received $100 million in cash at closing from Apotex Health for its FDA-approved product line and may receive up to $11 million more. According to Cumberland Pharmaceuticals, additional payments relate to product inventory and transitional support services following integration of U.S.-branded businesses.

What are the details of Cumberland Pharmaceuticals (CPIX) $5 million share repurchase program?

Cumberland’s Board authorized an open-market repurchase program of up to $5 million in company shares. According to Cumberland Pharmaceuticals, management will determine timing and volume based on stock price, trading activity, market conditions, and general business considerations, with several Board members also planning additional personal share purchases.

Which clinical programs is Cumberland Pharmaceuticals (CPIX) advancing for ifetroban?

Cumberland is advancing Phase 2 ifetroban studies in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and cancer metastasis. According to Cumberland Pharmaceuticals, these programs include FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations for the DMD cardiomyopathy indication and favorable safety findings.

What corrections were made to Cumberland Pharmaceuticals (CPIX) July 13, 2026 dividend announcement?

The corrected release updates the sub-headline and first paragraph record date from “July 10” to July 23. According to Cumberland Pharmaceuticals, it also includes updated wording in the third paragraph and adds a clarifying sentence after the first sentence of the fourth paragraph.